TD Cowen lowered the firm’s price target on Humacyte (HUMA) to $1 from $3.50 and keeps a Buy rating on the shares. The firm said its 2025 results matched the company’s preannouncement with product/total revenue of $1.4M/$2M below the firm’s $2.1/$2.8M estimates. Though the company showed continued clinical trial progress in AV Access, Cowen believes the early US Symvess launch trends along with the cash burn rate represent temporary overhangs for the stock.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUMA:
- Humacyte price target lowered to $1 from $3 at Piper Sandler
- Humacyte: Near-Term Commercial Headwinds but Platform Catalysts Support Long-Term Upside and Buy Rating
- Morning Movers: AstraZeneca jumps following tozorakimab trial results
- Humacyte reports Q4 EPS (13c), consensus (14c)
- Options Volatility and Implied Earnings Moves Today, March 27, 2026